Finally, our interest is to collate the evidence available regarding the clinical implications of MSR1 alterations in different pathologies of the immune system and its role in tumour-associated macrophages (TAMs) in cancer, especially as it has been proposed as a potential biomarker with prognostic value. The gene discussed is MSR1; the disease is cancer.